
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Topical tacrolimus is effective in treating anogenital lichen sclerosus, according to two case reports in the July issue of the Archives of Dermatology.